TGTX News & Events

Reports Q1 revenue $204.92M, consensus $201.21M. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "We are off to a strong start in 2026, with BRIUMVI performance exceeding expectations and momentum continuing to build. Growth is being driven by strong underlying demand, record new patient starts, and consistent commercial execution- reinforcing our belief that we remain early in the adoption curve for BRIUMVI. Based on this performance, we are significantly increasing our full-year U.S. BRIUMVI revenue guidance to $885-900 million and continue to see the brand as having a multi-billion-dollar potential before considering the impact of a subcutaneous BRIUMVI currently under development. With multiple near-term clinical catalysts and ongoing efforts to expand the franchise, we believe BRIUMVI is well-positioned to become a leading therapy in MS and a durable, long-term growth driver for TG."

TG Therapeutics announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous Briumvi, the company's anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis. Briumvi is currently approved in the United States and several ex-US territories as a one-hour intravenous infusion administered twice a year, following the starting dose, in adults with RMS.

In connection with the new facility, the Company's Board of Directors authorized an increase to its share repurchase program from $100 million to $300 million. As of March 18, 2026, the Company has repurchased approximately $38 million of common stock under the prior and existing share repurchase program at an average price of $28.98 per share.